PT3079669T - Composições de libertação retardada de linaclotida - Google Patents

Composições de libertação retardada de linaclotida

Info

Publication number: PT3079669T
Authority: PT; Portugal
Prior art keywords: linaclotide; delayed release; release compositions; compositions; delayed
Prior art date: 2013-12-11

Application number

PT148246556T

Other languages

English (en)

Original Assignee

Forest Laboratories Holdings Ltd

Ironwood Pharmaceuticals Inc

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

2013-12-11

Filing date

2014-12-11

Publication date

2020-11-30

Family has litigation

First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=52293217&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=PT3079669(T) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.

2014-12-11 Application filed by Forest Laboratories Holdings Ltd, Ironwood Pharmaceuticals Inc filed Critical Forest Laboratories Holdings Ltd

2020-11-30 Publication of PT3079669T publication Critical patent/PT3079669T/pt

Classifications

- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
- A61K38/10—Peptides having 12 to 20 amino acids
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
- A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
- A61K9/1605—Excipients; Inactive ingredients
- A61K9/1611—Inorganic compounds
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
- A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
- A61K9/1605—Excipients; Inactive ingredients
- A61K9/1617—Organic compounds, e.g. phospholipids, fats
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
- A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
- A61K9/1605—Excipients; Inactive ingredients
- A61K9/1629—Organic macromolecular compounds
- A61K9/1635—Organic macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyvinyl pyrrolidone, poly(meth)acrylates
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
- A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
- A61K9/1605—Excipients; Inactive ingredients
- A61K9/1629—Organic macromolecular compounds
- A61K9/1652—Polysaccharides, e.g. alginate, cellulose derivatives; Cyclodextrin
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
- A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
- A61K9/167—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction with an outer layer or coating comprising drug; with chemically bound drugs or non-active substances on their surface
- A61K9/1676—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction with an outer layer or coating comprising drug; with chemically bound drugs or non-active substances on their surface having a drug-free core with discrete complete coating layer containing drug
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2004—Excipients; Inactive ingredients
- A61K9/2009—Inorganic compounds
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2004—Excipients; Inactive ingredients
- A61K9/2013—Organic compounds, e.g. phospholipids, fats
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2004—Excipients; Inactive ingredients
- A61K9/2013—Organic compounds, e.g. phospholipids, fats
- A61K9/2018—Sugars, or sugar alcohols, e.g. lactose, mannitol; Derivatives thereof, e.g. polysorbates
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2004—Excipients; Inactive ingredients
- A61K9/2022—Organic macromolecular compounds
- A61K9/2027—Organic macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyvinyl pyrrolidone, poly(meth)acrylates
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2004—Excipients; Inactive ingredients
- A61K9/2022—Organic macromolecular compounds
- A61K9/205—Polysaccharides, e.g. alginate, gums; Cyclodextrin
- A61K9/2054—Cellulose; Cellulose derivatives, e.g. hydroxypropyl methylcellulose
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/28—Dragees; Coated pills or tablets, e.g. with film or compression coating
- A61K9/2806—Coating materials
- A61K9/2833—Organic macromolecular compounds
- A61K9/284—Organic macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyvinyl pyrrolidone
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/28—Dragees; Coated pills or tablets, e.g. with film or compression coating
- A61K9/2806—Coating materials
- A61K9/2833—Organic macromolecular compounds
- A61K9/284—Organic macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyvinyl pyrrolidone
- A61K9/2846—Poly(meth)acrylates
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/28—Dragees; Coated pills or tablets, e.g. with film or compression coating
- A61K9/2886—Dragees; Coated pills or tablets, e.g. with film or compression coating having two or more different drug-free coatings; Tablets of the type inert core-drug layer-inactive layer
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
- A61K9/4808—Preparations in capsules, e.g. of gelatin, of chocolate characterised by the form of the capsule or the structure of the filling; Capsules containing small tablets; Capsules with outer layer for immediate drug release
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
- A61K9/4816—Wall or shell material
- A61K9/4825—Proteins, e.g. gelatin
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
- A61K9/4841—Filling excipients; Inactive ingredients
- A61K9/485—Inorganic compounds
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
- A61K9/4841—Filling excipients; Inactive ingredients
- A61K9/4858—Organic compounds
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
- A61K9/4841—Filling excipients; Inactive ingredients
- A61K9/4866—Organic macromolecular compounds
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
- A61K9/4891—Coated capsules; Multilayered drug free capsule shells
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
- A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
- A61K9/5005—Wall or coating material
- A61K9/5021—Organic macromolecular compounds
- A61K9/5026—Organic macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyvinyl pyrrolidone, poly(meth)acrylates
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
- A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
- A61K9/5005—Wall or coating material
- A61K9/5021—Organic macromolecular compounds
- A61K9/5036—Polysaccharides, e.g. gums, alginate; Cyclodextrin
- A61K9/5042—Cellulose; Cellulose derivatives, e.g. phthalate or acetate succinate esters of hydroxypropyl methylcellulose
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/10—Laxatives
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/14—Prodigestives, e.g. acids, enzymes, appetite stimulants, antidyspeptics, tonics, antiflatulents
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00

Landscapes

Health & Medical Sciences (AREA)
Life Sciences & Earth Sciences (AREA)
Chemical & Material Sciences (AREA)
Animal Behavior & Ethology (AREA)
Veterinary Medicine (AREA)
Medicinal Chemistry (AREA)
Public Health (AREA)
General Health & Medical Sciences (AREA)
Pharmacology & Pharmacy (AREA)
Bioinformatics & Cheminformatics (AREA)
Engineering & Computer Science (AREA)
Epidemiology (AREA)
Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
General Chemical & Material Sciences (AREA)
Chemical Kinetics & Catalysis (AREA)
Organic Chemistry (AREA)
Inorganic Chemistry (AREA)
Molecular Biology (AREA)
Biophysics (AREA)
Gastroenterology & Hepatology (AREA)
Immunology (AREA)
Proteomics, Peptides & Aminoacids (AREA)
Nutrition Science (AREA)
Medicinal Preparation (AREA)
Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Peptides Or Proteins (AREA)
Endocrinology (AREA)
Zoology (AREA)
Pain & Pain Management (AREA)
Rheumatology (AREA)

PT148246556T 2013-12-11 2014-12-11 Composições de libertação retardada de linaclotida PT3079669T (pt)

Applications Claiming Priority (2)

Application Number	Priority Date	Filing Date	Title
US201361914951P	2013-12-11	2013-12-11
US201361914952P	2013-12-11	2013-12-11

Publications (1)

Publication Number	Publication Date
PT3079669T true PT3079669T (pt)	2020-11-30

Family

ID=52293217

Family Applications (1)

Application Number	Title	Priority Date	Filing Date
PT148246556T PT3079669T (pt)	2013-12-11	2014-12-11	Composições de libertação retardada de linaclotida

Country Status (28)

Country	Link
US (7)	US20160310559A1 (pt)
EP (2)	EP3079669B1 (pt)
JP (4)	JP6964380B2 (pt)
KR (3)	KR102337809B1 (pt)
CN (3)	CN106659687A (pt)
AU (3)	AU2014362220B2 (pt)
CA (1)	CA2933587C (pt)
CL (1)	CL2016001424A1 (pt)
CY (1)	CY1123953T1 (pt)
DK (1)	DK3079669T3 (pt)
EA (1)	EA201691216A1 (pt)
EC (2)	ECSP16059106A (pt)
ES (1)	ES2838007T3 (pt)
HR (1)	HRP20201753T1 (pt)
HU (1)	HUE052981T2 (pt)
IL (2)	IL246155A0 (pt)
LT (1)	LT3079669T (pt)
MX (2)	MX2016007625A (pt)
NZ (2)	NZ759512A (pt)
PE (2)	PE20211976A1 (pt)
PH (1)	PH12016501122A1 (pt)
PL (1)	PL3079669T3 (pt)
PT (1)	PT3079669T (pt)
RS (1)	RS61133B1 (pt)
SG (2)	SG11201604729QA (pt)
SI (1)	SI3079669T1 (pt)
UA (1)	UA119335C2 (pt)
WO (2)	WO2015089335A1 (pt)

Families Citing this family (18)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
UA119335C2 (uk) *	2013-12-11	2019-06-10	Айронвуд Фармасьютикалз, Інк.	Композиції лінаклотиду з затриманим вивільненням
TW201618783A (zh)	2014-08-07	2016-06-01	艾森塔製藥公司	以布魯頓(Bruton)氏酪胺酸激酶(BTK)佔據和BTK再合成速率為基礎之治療癌症、免疫和自體免疫疾病及發炎性疾病之方法
CA2936748C (en)	2014-10-31	2017-08-08	Purdue Pharma	Methods and compositions particularly for treatment of attention deficit disorder
US20180008547A1 (en) *	2015-02-02	2018-01-11	Aurobindo Pharma Ltd	Stable Compositions comprising Linaclotide
ES2868873T3 (es) *	2015-06-05	2021-10-22	Ironwood Pharmaceuticals Inc	Formulaciones de liberación modificada o dirigida de linaclotida
WO2017156214A1 (en) *	2016-03-11	2017-09-14	Gateway Pharmaceutical LLC	Pharmaceutical compositions for colon-specific delivery
US10588864B2 (en)	2016-03-11	2020-03-17	Gateway Pharmaceuticals LLC	Pharmaceutical compositions for colon-specific delivery
JP6957610B2 (ja) *	2016-10-06	2021-11-02	スキャンポ・アーゲーＳｕｃａｍｐｏＡＧ	医薬品用途のための多層ビーズ
JP2020512292A (ja) *	2016-12-21	2020-04-23	アイアンウッドファーマシューティカルズインコーポレイテッド	リナクロチドの改変放出製剤または遅延放出製剤による過敏性腸症候群の処置方法
KR102227486B1 (ko) *	2017-06-30	2021-03-12	롯데정밀화학 주식회사	프로톤 펌프 저해제를 포함하는 경구용 고형제제 조성물, 이를 포함하는 경구용 고형제제 및 그 제조방법
CA3095036A1 (en) *	2018-03-23	2019-09-26	Palatin Technologies, Inc.	Melanocortin receptor-specific peptide formulations and methods for gastrointestinal tract-specific delivery
US10722473B2 (en)	2018-11-19	2020-07-28	Purdue Pharma L.P.	Methods and compositions particularly for treatment of attention deficit disorder
JP2022536494A (ja) *	2019-06-10	2022-08-17	アイアンウッドファーマシューティカルズ，インコーポレイテッド	下痢型過敏性腸症候群に関連する腹痛の処置
KR102104507B1 (ko) *	2019-08-23	2020-04-24	브릿지바이오테라퓨틱스(주)	팔미토일-l-프롤릴-l-프롤릴-글리실-l-타이로신 나트륨을 포함하는 약제학적 제제 및 이의 제조방법
CN110935007B (zh) *	2019-12-12	2023-06-23	烟台大学	利那洛肽复方组合物、制剂及其用途和制备方法
WO2022245650A1 (en) *	2021-05-19	2022-11-24	Alberto Paz	Orally administered compositions for cancer treatment
TW202426473A (zh) *	2022-10-03	2024-07-01	全福生物科技股份有限公司	包含pedf衍生短肽(pdsp)之組合物及其用途
WO2024143501A1 (ja) *	2022-12-28	2024-07-04	中外製薬株式会社	分散対象物質を含む固体分散体、それを含む医薬組成物及びそれらの製造方法

Family Cites Families (18)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
US7371727B2 (en)	2003-01-28	2008-05-13	Microbia, Inc.	Methods and compositions for the treatment of gastrointestinal disorders
US7304036B2 (en)	2003-01-28	2007-12-04	Microbia, Inc.	Methods and compositions for the treatment of gastrointestinal disorders
CN201252259Y (zh) *	2008-07-24	2009-06-03	富士康(昆山)电脑接插件有限公司	电连接器
CN114668711A (zh) *	2008-08-15	2022-06-28	硬木药品公司	适合口服给药的鸟苷酸环化酶-c受体激动剂多肽的稳定的固体制剂
EP2373296B1 (en) *	2008-12-03	2016-08-03	Synergy Pharmaceuticals Inc.	Formulations of guanylate cyclase c agonists and methods of use
US20130012454A1 (en) *	2009-07-06	2013-01-10	Ironwood Pharmaceuticals, Inc.	Orally Disintegrating Compositions of Linaclotide
US8748573B2 (en) *	2009-08-06	2014-06-10	Ironwood Pharmaceuticals, Inc.	Formulations comprising linaclotide
MX2012001691A (es) *	2009-08-12	2012-02-29	Forest Lab Holdings Ltd	Composiciones de linaclotida que se desintegran oralmente.
RU2012109415A (ru) *	2009-08-13	2013-09-20	Айронвуд Фармасьютикалз, Инк.	Способ модуляции фармакодинамического эффекта перорально вводимых агонистов рецептора гуанилатциклазы
EP2536742B1 (en) *	2010-02-17	2017-07-19	Ironwood Pharmaceuticals, Inc.	Treatments for gastrointestinal disorders
EP2603232B1 (en) *	2010-08-11	2019-09-25	Ironwood Pharmaceuticals, Inc.	Stable formulations of linaclotide
CN103702678A (zh) *	2010-09-11	2014-04-02	硬木药品公司	便秘型肠易激综合征的治疗
JP2012155108A (ja) *	2011-01-26	2012-08-16	Kyocera Document Solutions Inc	現像ローラ、現像装置および画像形成装置
ES2614864T3 (es) *	2011-08-17	2017-06-02	Ironwood Pharmaceuticals, Inc.	Tratamientos para trastornos gastrointestinales
BR112014007753B1 (pt) *	2011-09-30	2021-07-06	Astellas Pharma Inc.	composição farmacêutica granular, formulação e método para produção
WO2014088623A1 (en) *	2012-07-12	2014-06-12	Forest Laboratories Holdings Limited	Linaclotide compositions
JP6499591B2 (ja) *	2013-02-25	2019-04-10	シナジーファーマシューティカルズインコーポレイテッド	結腸洗浄において用いるためのグアニル酸シクラーゼ受容体アゴニスト
UA119335C2 (uk) *	2013-12-11	2019-06-10	Айронвуд Фармасьютикалз, Інк.	Композиції лінаклотиду з затриманим вивільненням

2014
- 2014-11-12 UA UAA201607434A patent/UA119335C2/uk unknown
- 2014-12-11 WO PCT/US2014/069851 patent/WO2015089335A1/en active Application Filing
- 2014-12-11 EA EA201691216A patent/EA201691216A1/ru unknown
- 2014-12-11 JP JP2016538745A patent/JP6964380B2/ja active Active
- 2014-12-11 EP EP14824655.6A patent/EP3079669B1/en active Active
- 2014-12-11 US US15/103,616 patent/US20160310559A1/en not_active Abandoned
- 2014-12-11 DK DK14824655.6T patent/DK3079669T3/da active
- 2014-12-11 MX MX2016007625A patent/MX2016007625A/es unknown
- 2014-12-11 PT PT148246556T patent/PT3079669T/pt unknown
- 2014-12-11 NZ NZ759512A patent/NZ759512A/en unknown
- 2014-12-11 PL PL14824655T patent/PL3079669T3/pl unknown
- 2014-12-11 CN CN201480075352.1A patent/CN106659687A/zh active Pending
- 2014-12-11 SG SG11201604729QA patent/SG11201604729QA/en unknown
- 2014-12-11 EP EP20198666.8A patent/EP3821881A1/en active Pending
- 2014-12-11 KR KR1020167018606A patent/KR102337809B1/ko active IP Right Grant
- 2014-12-11 LT LTEP14824655.6T patent/LT3079669T/lt unknown
- 2014-12-11 WO PCT/US2014/069838 patent/WO2015089326A1/en active Application Filing
- 2014-12-11 CA CA2933587A patent/CA2933587C/en active Active
- 2014-12-11 US US15/103,634 patent/US20160310560A1/en not_active Abandoned
- 2014-12-11 NZ NZ721952A patent/NZ721952A/en unknown
- 2014-12-11 CN CN202011156517.1A patent/CN112569199A/zh active Pending
- 2014-12-11 SI SI201431715T patent/SI3079669T1/sl unknown
- 2014-12-11 AU AU2014362220A patent/AU2014362220B2/en active Active
- 2014-12-11 RS RS20201435A patent/RS61133B1/sr unknown
- 2014-12-11 KR KR1020217039962A patent/KR102509291B1/ko active IP Right Grant
- 2014-12-11 HU HUE14824655A patent/HUE052981T2/hu unknown
- 2014-12-11 PE PE2021000748A patent/PE20211976A1/es unknown
- 2014-12-11 PE PE2016000804A patent/PE20161373A1/es unknown
- 2014-12-11 CN CN202210517834.4A patent/CN115089556A/zh active Pending
- 2014-12-11 ES ES14824655T patent/ES2838007T3/es active Active
- 2014-12-11 KR KR1020237008167A patent/KR20230039764A/ko not_active Application Discontinuation
- 2014-12-11 SG SG10201804817TA patent/SG10201804817TA/en unknown
2016
- 2016-06-09 IL IL246155A patent/IL246155A0/en unknown
- 2016-06-10 MX MX2021011906A patent/MX2021011906A/es unknown
- 2016-06-10 PH PH12016501122A patent/PH12016501122A1/en unknown
- 2016-06-10 CL CL2016001424A patent/CL2016001424A1/es unknown
- 2016-07-08 EC ECIEPI201659106A patent/ECSP16059106A/es unknown
2017
- 2017-02-17 US US15/435,701 patent/US20170157200A1/en not_active Abandoned
- 2017-09-28 US US15/718,075 patent/US20180015139A1/en not_active Abandoned
2019
- 2019-02-21 JP JP2019029432A patent/JP2019073559A/ja active Pending
- 2019-09-11 US US16/567,082 patent/US20200038476A1/en not_active Abandoned
2020
- 2020-04-01 AU AU2020202319A patent/AU2020202319B2/en active Active
- 2020-10-30 HR HRP20201753TT patent/HRP20201753T1/hr unknown
- 2020-11-26 CY CY20201101128T patent/CY1123953T1/el unknown
2021
- 2021-05-06 IL IL283012A patent/IL283012A/en unknown
- 2021-05-06 JP JP2021078445A patent/JP7483656B2/ja active Active
- 2021-09-28 EC ECSENADI202172161A patent/ECSP21072161A/es unknown
- 2021-10-18 US US17/503,601 patent/US20220031802A1/en not_active Abandoned
2022
- 2022-03-18 AU AU2022201891A patent/AU2022201891A1/en not_active Abandoned
2023
- 2023-07-14 JP JP2023115832A patent/JP2023126475A/ja active Pending
- 2023-11-09 US US18/505,414 patent/US20240075094A1/en active Pending

Also Published As

Publication number	Publication date
PH12016501122A1 (en)	2016-07-18
US20180015139A1 (en)	2018-01-18
JP2019073559A (ja)	2019-05-16
EP3821881A1 (en)	2021-05-19
CN115089556A (zh)	2022-09-23
PE20211976A1 (es)	2021-10-05
EP3079669B1 (en)	2020-09-30
SG11201604729QA (en)	2016-07-28
CN106659687A (zh)	2017-05-10
KR20210152588A (ko)	2021-12-15
ECSP21072161A (es)	2021-11-18
US20240075094A1 (en)	2024-03-07
WO2015089335A1 (en)	2015-06-18
KR20230039764A (ko)	2023-03-21
IL283012A (en)	2021-06-30
HUE052981T2 (hu)	2021-05-28
JP6964380B2 (ja)	2021-11-10
US20200038476A1 (en)	2020-02-06
WO2015089326A9 (en)	2016-08-04
BR112016013419A2 (pt)	2017-09-26
UA119335C2 (uk)	2019-06-10
JP7483656B2 (ja)	2024-05-15
RS61133B1 (sr)	2020-12-31
CY1123953T1 (el)	2022-03-24
AU2020202319B2 (en)	2022-03-24
AU2022201891A1 (en)	2022-04-07
KR102509291B1 (ko)	2023-03-14
JP2023126475A (ja)	2023-09-07
EA201691216A1 (ru)	2016-11-30
ECSP16059106A (es)	2017-02-24
NZ759512A (en)	2022-05-27
US20220031802A1 (en)	2022-02-03
AU2014362220B2 (en)	2020-04-30
DK3079669T3 (da)	2020-11-02
MX2016007625A (es)	2016-12-09
KR102337809B1 (ko)	2021-12-10
ES2838007T3 (es)	2021-07-01
WO2015089326A1 (en)	2015-06-18
JP2017504590A (ja)	2017-02-09
JP2021113227A (ja)	2021-08-05
SG10201804817TA (en)	2018-07-30
NZ721952A (en)	2022-05-27
PE20161373A1 (es)	2016-12-17
LT3079669T (lt)	2020-12-10
US20160310559A1 (en)	2016-10-27
AU2014362220A1 (en)	2016-06-30
US20170157200A1 (en)	2017-06-08
IL246155A0 (en)	2016-07-31
AU2020202319A1 (en)	2020-04-23
US20160310560A1 (en)	2016-10-27
KR20160132001A (ko)	2016-11-16
HRP20201753T1 (hr)	2020-12-25
CN112569199A (zh)	2021-03-30
CA2933587A1 (en)	2015-06-18
SI3079669T1 (sl)	2021-01-29
CL2016001424A1 (es)	2017-09-08
MX2021011906A (es)	2021-10-26
EP3079669A1 (en)	2016-10-19
PL3079669T3 (pl)	2021-04-06
CA2933587C (en)	2023-09-26

Publication	Publication Date	Title
IL283012A (en)	2021-06-30	Sustained release formulations of linclotide
IL289821B (en)	2022-12-01	Preparations and methods for immunotherapy
HK1220387A1 (zh)	2017-05-05	用於免疫療法的組合物和方法
IL244850B (en)	2020-04-30	Stabilized epinaconazole preparations, and their uses
GB201304662D0 (en)	2013-05-01	Compositions
IL285527A (en)	2021-09-30	Preparations and methods for immunotherapy
GB201313615D0 (en)	2013-09-11	Compositions
HK1220697A1 (zh)	2017-05-12	肽組合物
HK1216839A1 (zh)	2016-12-09	調整釋放製劑
GB201320962D0 (en)	2014-01-08	Compositions
IL240171A0 (en)	2015-09-24	A crystalline form of linaclotide
GB201320959D0 (en)	2014-01-08	Compositions
GB201312224D0 (en)	2013-08-21	Compositions
GB201304927D0 (en)	2013-05-01	Compositions